These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 8195041

  • 21. Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine.
    Saikawa Y, Kubota T, Kuo TH, Furukawa T, Tanino H, Watanabe M, Ishibiki K, Kitajima M.
    Jpn J Cancer Res; 1993 Jul; 84(7):787-93. PubMed ID: 8370654
    [Abstract] [Full Text] [Related]

  • 22. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X radiation.
    Shrieve DC, Harris JW.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1171-4. PubMed ID: 3744936
    [Abstract] [Full Text] [Related]

  • 23. Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo.
    Bier H.
    Acta Otolaryngol; 1991 Jul; 111(4):797-806. PubMed ID: 1950544
    [Abstract] [Full Text] [Related]

  • 24. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR.
    J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
    [Abstract] [Full Text] [Related]

  • 25. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
    Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC.
    Pigment Cell Res; 1997 Aug; 10(4):236-49. PubMed ID: 9263331
    [Abstract] [Full Text] [Related]

  • 26. Effect of L-dopa methylester and glutathione depletion on murine B16BL6 melanoma growth in vitro.
    Thrall BD, Meadows GG.
    J Invest Dermatol; 1991 Dec; 97(6):1073-7. PubMed ID: 1748817
    [Abstract] [Full Text] [Related]

  • 27. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
    Dethlefsen LA, Lehman CM, Biaglow JE, Peck VM.
    Radiat Res; 1988 May; 114(2):215-24. PubMed ID: 3375425
    [Abstract] [Full Text] [Related]

  • 28. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
    Kang YJ.
    Cell Mol Biol Res; 1995 May; 41(2):131-6. PubMed ID: 8581064
    [Abstract] [Full Text] [Related]

  • 29. Effects of the long-term depletion of reduced glutathione in mice administered L-buthionine-S,R-sulfoximine.
    Sun JD, Ragsdale SS, Benson JM, Henderson RF.
    Fundam Appl Toxicol; 1985 Oct; 5(5):913-9. PubMed ID: 2866140
    [Abstract] [Full Text] [Related]

  • 30. Long-term buthionine-sulfoximine-mediated toxicity in cultured hepatoma cell lines.
    Dierickx PJ.
    Res Commun Chem Pathol Pharmacol; 1990 Mar; 67(3):423-6. PubMed ID: 2160706
    [Abstract] [Full Text] [Related]

  • 31. Selenite-induced inhibition of colony formation by buthionine sulfoximine-sensitive and resistant cell lines.
    Caffrey PB, Frenkel GD.
    Biol Trace Elem Res; 1992 Nov; 35(2):129-36. PubMed ID: 1280979
    [Abstract] [Full Text] [Related]

  • 32. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
    Xu BH, Gupta V, Singh SV.
    Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448
    [Abstract] [Full Text] [Related]

  • 33. The toxic effects, GSH depletion and radiosensitivity by BSO on retinoblastoma.
    Yi X, Ding L, Jin Y, Ni C, Wang W.
    Int J Radiat Oncol Biol Phys; 1994 May 15; 29(2):393-6. PubMed ID: 8195039
    [Abstract] [Full Text] [Related]

  • 34. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
    Hansson J, Edgren M, Ehrsson H, Ringborg U, Nilsson B.
    Cancer Res; 1988 Jan 01; 48(1):19-26. PubMed ID: 3334994
    [Abstract] [Full Text] [Related]

  • 35. Differential cytotoxicity of buthionine sulfoximine to "normal" and transformed human lung fibroblast cells.
    Wan XS, St Clair DK.
    Cancer Chemother Pharmacol; 1993 Jan 01; 33(3):210-4. PubMed ID: 8269602
    [Abstract] [Full Text] [Related]

  • 36. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro.
    Shrieve DC, Denekamp J, Minchinton AI.
    Radiat Res; 1985 Jun 01; 102(3):283-94. PubMed ID: 4070545
    [Abstract] [Full Text] [Related]

  • 37. Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine.
    Ono K, Shrieve DC.
    Int J Radiat Oncol Biol Phys; 1986 Jul 01; 12(7):1175-8. PubMed ID: 3091546
    [Abstract] [Full Text] [Related]

  • 38. Buthionine sulfoximine spares intracellular glutamate: a possible mechanism for cell growth stimulation.
    Kang YJ.
    Cell Mol Biol Res; 1993 Jul 01; 39(7):675-84. PubMed ID: 8055000
    [Abstract] [Full Text] [Related]

  • 39. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells.
    Dusre L, Mimnaugh EG, Myers CE, Sinha BK.
    Cancer Res; 1989 Feb 01; 49(3):511-5. PubMed ID: 2535960
    [Abstract] [Full Text] [Related]

  • 40. The effect of glutathione (GSH) depletion in vivo by buthionine sulfoximine (BSO) on the radiosensitization of SR 2508.
    Kramer RA, Soble M, Howes AE, Montoya VP.
    Int J Radiat Oncol Biol Phys; 1989 May 01; 16(5):1325-9. PubMed ID: 2523885
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.